Primaquine Phosphate + Mao Inhibitors Interaction
Majorinteraction on record
Description
Concomitant use in patients with reduced or absent CYP2D6 activity may increase primaquine exposure and risk of adverse reactions; defer initiation or increase monitoring.
Mechanism
Increased primaquine exposure in patients with reduced CYP2D6 activity
Source: NLP:primaquine phosphate